Imaging

Electrophysiology

Genetics

Canadian Society of Cardiovascular MRI (CSCMRI)

352 - CSCMRI SPOTLIGHT: THE EVOLVING ROLE OF GENETICS AND CARDIAC MRI IN THE DIAGNOSIS AND MANAGEMENT OF GENETIC CARDIOMYOPATHIES.

Co-Chair(s)

• MC

  Michael Chetrit, MD

  Cardiologist
  McGill University Health Centre Research Institute
  McGill University
• 

  Judy Luu, MD/PhD

  Cardiologist
  McGill University Health Centre
  McGill University

Presenter(s)

• 

  Sarah Blissett, MD MHPE FRCPC

  MD
  London Health Sciences Centre
  Western University
• MP

  Martine Parent, MD
• 

  Maxime Tremblay-Gravel, MD MSc (he/him/his)

  Cardiologist
  Institut de Cardiologie de Montréal
  Université de Montréal

Early Career(s)

• MP

  Martine Parent, MD

Trainee(s)

• BM

  Bethlehem Mengesha, Cardiologist, multimodality cardiac imager

  Clinical and research fellow
  University of Ottawa heart institute

Moderator(s)

• MC

  Michael Chetrit, MD

  Cardiologist
  McGill University Health Centre Research Institute
  McGill University

Planning Committee Member(s)

• 

  Jacqueline Joza, MD MSc

  Cardiologist
  CHRS
  McGill University Health Centre
• 

  Andreas Kumar, MD MSc (he/him/his)

  Cardiologist
  HSN Sudbury, NOSM University
  Northern Ontario School of Medicine
• BM

  Bethlehem Mengesha, Cardiologist, multimodality cardiac imager

  Clinical and research fellow
  University of Ottawa heart institute
• MP

  Martine Parent, MD
• 

  Ian Paterson, MD, FRCPC

  Cardiologist
  CSE, CSCMRI, CardioOncology
• IR

  Idan Roifman, Director of Multimodality Imaging, Reichmann Family Chair for Cardiovascular Research

  Cardiologist
  CSCMRI
  University of Toronto

Workshop Description: Cardiomyopathies are intrinsic conditions affecting the heart muscle. They are classified into three primary types based on structural characteristics and arrhythmic tendencies: hypertrophic cardiomyopathy (HCM), marked by thickened cardiac muscle and impaired relaxation; dilated cardiomyopathy (DCM), characterized by an enlarged left ventricle and weakened contraction; and arrhythmogenic cardiomyopathy (ACM), which can affect the right, left, or both ventricles. Advances in genetics are uncovering the molecular foundations of these diseases, enabling more precise diagnosis and treatment while elucidating the mechanisms behind their distinct clinical manifestations. This growing knowledge has driven the development of novel therapies, including targeted pharmacological treatments that address underlying disease processes and emerging gene therapies designed to halt disease progression and restore normal heart function. This workshop will focus on a case-based approach to the assessment of the three major categories of genetic cardiomyopathies including genetic testing, multimodality cardiac imaging and novel therapies.